New COVID “Cicada” Variant BA.3.2: Symptoms, Vaccine Efficacy & Updates 2026

Health authorities in the United States and abroad are closely monitoring a new Omicron subvariant of COVID-19 known as BA.3.2. Informally nicknamed “Cicada,” the variant has attracted attention from the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) due to its genetic characteristics and spread across multiple regions. While the variant is not currently dominant, officials are tracking its potential to evade immunity from previous infections or vaccinations.

Global and Domestic Spread

According to CDC reports, the BA.3.2 variant has been detected in at least 25 states within the United States as of February 11, 2026. Globally, the virus has been reported in more than 20 countries, including Japan, Kenya, the Netherlands, and the United Kingdom. In some nations, the variant accounts for up to 30% of cases, though it has yet to represent a significant number of cases across the United States as a whole.

The WHO listed the highly mutated virus on its “variants of monitoring” record on February 23, 2026. This classification follows detections cropping up in various countries over recent months. The CDC noted in a March 19, 2026 report that routine surveillance had observed a steady incline in U.S. Cases linked to the lineage.

Origin and Characteristics

The nickname “Cicada” was assigned to BA.3.2 by T. Ryan Gregory, Ph.D., a professor of evolutionary biology at the University of Guelph. The name references the insect’s habit of remaining underground for long periods before re-emerging. Similarly, this variant spent its first few years largely undetected or “underground” before surfacing as a potential major variant. Dr. Robert H. Hopkins, Jr., medical director of the National Foundation for Infectious Diseases, noted that the variant was first detected in a person traveling to the United States in June 2025.

BA.3.2 belongs to the Omicron family but stands out due to a high number of genetic changes. Reporting indicates the variant possesses an estimated 70 to 75 mutations. Andrew Pekosz, Ph.D., a virologist at the Johns Hopkins Bloomberg School of Public Health, explained that the variant has a slew of genetic changes in its spike protein that set it apart from other circulating strains.

It has a lot of mutations that may cause it to look different to your immune system.

Andrew Pekosz, Ph.D., Johns Hopkins Bloomberg School of Public Health

Severity and Symptoms

Despite the high number of mutations, available data does not show a general increase in the severity of cases caused by BA.3.2. The CDC indicates that hospitalizations remain stable or are declining, and visits to the emergency room do not show significant increases. There is currently no clear evidence of increased lethality associated with this subvariant.

Celine Gounder, a public health expert, stated that there is no evidence that this variant causes more severe disease or an increase in hospitalizations. However, local increases in infections may vary by region, with states such as Massachusetts and Florida potentially seeing fluctuations.

Clinically, the symptoms associated with the BA.3.2 variant do not differ from those already known for COVID-19. Patients infected with the Cicada variant typically present with standard symptoms, including:

• Fever
• Cough
• Difficulty breathing
• Sore throat
• Nasal congestion

Vaccine Protection and Immune Evasion

The primary concern among health officials is the variant’s potential ability to escape immunity. A study published in the CDC’s Morbidity and Mortality Weekly Report suggests that the mutations have the potential to reduce protection from a previous infection or vaccination. However, current vaccines still offer partial protection, particularly against serious illness.

Amesh A. Adalja, M.D., a senior scholar at the Johns Hopkins Center for Health Security, described BA.3.2 as another variant of Omicron that has evolved several mutations making it more difficult for the immune system to completely neutralize. Monitoring the spread provides valuable information about the potential for this new SARS-CoV-2 lineage to evade immunity.

Public Health Recommendations

The CDC maintains recommendations focused on higher-risk groups to strengthen protection against the variant. These groups include people 65 years or older, individuals who have not been vaccinated, patients with chronic diseases such as heart or lung conditions and diabetes, and people with weakened immune systems.

Regarding timing for vaccination, infectious disease specialist William Schaffner recommended a specific window for optimal protection against potential summer surges.

Get vaccinated in late May or early June to have some protection against the surge in cases over the summer.

William Schaffner, M.D., Professor and Chief of Infectious Diseases

For the general population, health experts advise maintaining basic measures such as staying up to date with vaccinations, monitoring symptoms, and following official information from health authorities. While the variant is hyper-mutated and being closely tracked, officials emphasize that it is not currently considered more dangerous than other circulating strains. The evolution of BA.3.2 remains under international surveillance as researchers continue to evaluate its real impact on public health in 2026.